| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 22 | ₹5,016 |
| HNI / NII | 40 | 880 | ₹2,00,640 |
| bHNI / bNII | 200 | 4,400 | ₹10,03,200 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 75,79,487 (60.00%) | — | ₹17,811.80 Cr |
| NII / HNI (Total) | — | 12,63,247 (10.00%) | — | ₹2,968.63 Cr |
| Retail Investors | — | 37,89,743 (30.00%) | — | ₹8,905.90 Cr |
| Total ** | — | 1,26,32,477 (100.00%) | — | ₹296,863.21 Cr |
| Metric | 31-Dec-09 | 31-Dec-08 | 31-Dec-07 |
|---|---|---|---|
| Revenue | 759.40 | 763.90 | 623.81 |
| PAT | 130.38 | 108.39 | 83.27 |
| EBITDA | — | — | — |
| Net Worth | — | — | — |
| Total Assets | — | — | — |
| Reserves | — | — | — |
| Borrowings | — | — | — |
Incorporated in 1994, Claris Lifesciences Limited (CLL) is an Ahmedabad based pharmaceutical company. Claris is the largest Indian sterile injectables pharmaceutical companies with a presence in 76 countries worldwide. Claris offers 113 products across multiple markets and therapeutic areas. All of these products are off-patent products.
Claris's product range across various therapeutic segments, including anaesthesia, critical care, anti-infectives, renal care, infusion therapy, enteral nutrition, parenteral nutrition and oncology.
Companies more than half of the sales come from international markets and have a strong presence in regions of Latin America, the Middle East, Africa and Central, South East and Far East Asia.
Claris's manufacturing facilities are located in Ahmedabad, India and approved by foreign regulatory authorities. The manufacturing facilities are ISO 9001-2000 and WHO GMP certified.